Recombinant CD4 (Ibalizumab Biosimilar) antibody

Catalog No. ABIN7795119

The Mouse Monoclonal anti-CD4 (Ibalizumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect CD4 (Ibalizumab Biosimilar) in samples from Human.

Quick Overview for Recombinant CD4 (Ibalizumab Biosimilar) antibody (ABIN7795119)

Target: CD4 (Ibalizumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This CD4 (Ibalizumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD4 (Ibalizumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Ibalizumab Biosimilar, Human CD4 Monoclonal Antibody

Characteristics: What is ibalizumab biosimilar research grade? Ibalizumab Biosimilar uses the same protein sequences as the therapeutic antibody ibalizumab which is a non-immunosuppressive humanised monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits HIV from entering cells. It is a post-attachment inhibitor, blocking HIV from binding to the CCR5 and CXCR4 co-receptors after HIV binds to the CD4 receptor on the surface of a CD4 cell. Post-attachment inhibitors are a subclass of HIV drugs called entry inhibitors.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD4

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD4 (Ibalizumab Biosimilar)

Target: CD4 (Ibalizumab Biosimilar)

Alternative Name: Ibalizumab Biosimilar

Target Type: Biosimilar